A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

LESSONS LEARNED. Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents. The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited efficacy in the patient population tested. BACKGR...

Descripción completa

Detalles Bibliográficos
Autores principales: Lieu, Christopher H., Hidalgo, Manuel, Berlin, Jordan D., Ko, Andrew H., Cervantes, Andres, LoRusso, Patricia, Gerber, David E., Eder, J. Paul, Eckhardt, S. Gail, Kapp, Amy V., Tsuhako, Amy, McCall, Bruce, Pirzkall, Andrea, Uyei, Anne, Tabernero, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599193/
https://www.ncbi.nlm.nih.gov/pubmed/28592615
http://dx.doi.org/10.1634/theoncologist.2017-0175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599193/
https://www.ncbi.nlm.nih.gov/pubmed/28592615
http://dx.doi.org/10.1634/theoncologist.2017-0175

Ejemplares similares